España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

ge healthcare bio-sciences, s.a.u. - taurocolico acido - cÁpsula dura - 370 kbq - taurocolico acido 370 kbq - selenio (75se) acido tauroselcólico

Venezuela - español - Instituto Nacional de Higiene

laboratorios stiefel de venezuela, s.a. - hidrocortisona - locion - 1 % (a1)

Venezuela - español - Instituto Nacional de Higiene

laboratorios stiefel de venezuela, s.a. - hidrocortisona - locion - 2,5 %(a1)

Unión Europea - español - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rechazo del injerto - inmunosupresores - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Unión Europea - español - EMA (European Medicines Agency)

amgen europe bv - apremilast - arthritis, psoriatic; psoriasis - inmunosupresores - psoriásica arthritisotezla, solo o en combinación con fármacos antirreumáticos modificadores de la enfermedad (dmard), está indicado para el tratamiento de los activos de la artritis psoriásica (psa) en pacientes adultos que han tenido una respuesta inadecuada o que han sido intolerantes a una anterior, una terapia con dmard. psoriasisotezla está indicado para el tratamiento de moderada a severa psoriasis en placas crónica en pacientes adultos que no han respondido o que tienen una contraindicación de, o intolerancia a la otra terapia sistémica incluyendo ciclosporina, metotrexato o psoraleno y luz ultravioleta la luz (puva).

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

maskaf s.a.c. -

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

especialidades farmaceuticas centrum s.a. - levofloxacino - comprimido recubierto con pelÍcula - 500 mg - levofloxacino 500 mg - levofloxacino

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

arafarma group s.a. - ciprofloxacino hidrocloruro - comprimido recubierto con pelÍcula - 250 mg - ciprofloxacino hidrocloruro 250 mg - ciprofloxacino

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

arafarma group s.a. - ciprofloxacino hidrocloruro - comprimido recubierto con pelÍcula - 500 mg - ciprofloxacino hidrocloruro 500 mg - ciprofloxacino

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

arafarma group s.a. - ciprofloxacino hidrocloruro - comprimido recubierto con pelÍcula - 750 mg - ciprofloxacino hidrocloruro 750 mg - ciprofloxacino